The DOI matches its Crossref record; 826 of the 826 references it cites were found in a registry or an index.
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision
Open accessAbstract
In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo- or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 801–826 of 826
Obsessive-Compulsive Disorder:An Open-Label Pilot Trial of Escitalopram
Almeida, A. G.-D., Quarantini, L. C., Góis, C. R., Santos‐Jesus, R., Miranda‐Scippa, Â., de Oliveira, I. R., Prado, H. D. S., Leckman, J. F., & do Rosário, M. C. (2007) · CNS Spectrums · doi:10.1017/s1092852900021258 · Cited by 15
The neurobiology of social phobia: From pharmacotherapy to brain imaging
Ameringen, M. V., Mancini, C., Farvolden, P., & Oakman, J. M. (2000) · Current Psychiatry Reports · doi:10.1007/s11920-000-0082-7 · Cited by 15
Lepola, U. M., Heikkinen, H., Rimón, R., & Riekkinen, P. J. (1990) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470050209 · Cited by 15
Dell’Osso, B. M., Mundo, E., & Altamura, A. C. (2006) · CNS Spectrums · doi:10.1017/s1092852900015029 · Cited by 15
Escitalopram in the treatment of obsessive–compulsive disorder
Zohar, J. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.3.339 · Cited by 14
Self-citationAmore, M., Magnani, K., Cerisoli, M., & Ferrari, G. (1999) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/(sici)1099-1077(199908)14:6<429::aid-hup108>3.0.co;2-3 · Cited by 14
Amore, M., Magnani, K., Cerisoli, M., & Ferrari, G. (1999) · Human Psychopharmacology Clinical and Experimental · Cited by 14
Mindus, P., Nyman, H., Mogard, J., Meyerson, B. A., & Ericson, K. (1990) · Nordic Journal of Psychiatry · doi:10.3109/08039489009096568 · Cited by 14
Clomipramine and fluoxetine effects in the treatment of panic disorder
Čavaljuga, S., Ličanin, I., Kapić, E., & Potkonjak, D. (2003) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2003.3524 · Cited by 13
Serotonergic probes in obsessive compulsive disorder
Zohar, J., & Kindler, S. (1992) · International Clinical Psychopharmacology · doi:10.1097/00004850-199206001-00010 · Cited by 13
Self-citationMarfan's Syndrome and neuropsychiatric symptoms: Case report and literature review
Leone, J. C., & Swigar, M. E. (1986) · Comprehensive Psychiatry · doi:10.1016/0010-440x(86)90049-0 · Cited by 13
Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder
Fontenelle, L. F., Mendlowicz, M. V., Miguel, E. C., & Versiani, M. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510029740 · Cited by 13
Agid, O., Shalev, A. Y., & Lerer, B. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0306 · Cited by 12
Effectiveness of behavior treatment for panic disorder with and without agoraphobia
Barlow, D. H. (1994) · Medical Entomology and Zoology · Cited by 12
Teusch, L., Böhme, H., & Finke, J. (2001) · PubMed · doi:10.1007/s001150050709 · Cited by 10
Treatment of negative crises (panic attacks)
Dyukova, G. M., Shepeleva, I. P., & Ov, V. (1992) · Neuroscience and Behavioral Physiology · doi:10.1007/bf01182877 · Cited by 9
Negative Outcome After IMeurosurgery for Refractory Obsessive-compulsive Spectrum Disorder
Yaryura-Tobias, J. A., Stevens, K. P., Pérez-Rivera, R., Boullosa, O., & Neziroglu, F. A. (2000) · The World Journal of Biological Psychiatry · doi:10.3109/15622970009150592 · Cited by 8
Otsuka, T., Togo, T., Sugiyama, N., Uehara, K., Yoshimi, A., Karashima, A., Shioya, H., & Hirayasu, Y. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.10.014 · Cited by 8
Meta-Analysis of Anxiety Disorder Treatment Studies
Cox, B. J., Swinson, R. P., & Lee, P. S. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199208000-00027 · Cited by 7
Marks, I., Lovell, K., Noshirvani, H., Livanou, M., & Thrasher, S. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.4.317 · Cited by 5
Clinical effects of fluvoxamine on panic symptomatology.
Pols, H., Zandergen, J., de Loof, C., Fernandez, I., & Griez, E. J. L. (1994) · PubMed · Cited by 5
Högberg, U., & Wang, M. (2005) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2004.11.042 · Cited by 2
Psychosocial treatment for generalised anxiety disorder
Td, B. (1996) · Cited by 2
Efficacy of Paroxetine for Relapse Prevention in Social Anxiety Disorder: A 24-Week Study
Stein, D. J., Versiani, M., Hair, T., & Kumar, R. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.12.1111
Lorberbaum (1999) · doi:10.1002/(sici)1520-6394(1999)10:3
Economic costs of anxiety disorders
DuPont, R. L., Rice, D. P., Miller, L. S., Shiraki, S. S., Rowland, C. R., & Harwood, H. J. (1996) · Anxiety · doi:10.1002/(sici)1522-7154(1996)2:4<167::aid-anxi2>3.0.co;2-l
Research works printed but not linked: 116
- Altshuler LL, 2001, Postgrad Med, 1
- Amore M, 1999, Hum Psychopharmacol Clin Exp, 14, 435, 10.1002/(SICI)1099-1077(199908)14:6<435::AID-HUP109>3.0.CO;2-B · doi:10.1002/(sici)1099-1077(199908)14:6<435::aid-hup109>3.0.co;2-b
- Bakish D, 1996, Psychopharmacol Bull, 32, 135
- Ballenger JC, 2001, J Clin Psychiatry, 62, 53
- Bandelow B, 2004, Br J Psychiatry, 184, 271, 10.1192/bjp.184.3.271 · DOI
- Bandelow B, 2002, Eur Neuropsychopharmacol, 12, S364, 10.1016/S0924-977X(02)80585-5 · doi:10.1016/s0924-977x(02)80585-5
- Bradwejn J, 1993, Can J Psychiatry, 38, S109
- Braun P, 1990, J Clin Psychiatry, 51, 236
- Bystritsky A, 2008, Psychopharmacol Bull, 41, 46
- 10.3109/10401239909147053 · doi:10.3109/10401239909147053
- Chao IL, 2004, Pharmacopsychiatry, 37, 239, 10.1055/s-2004-832600 · DOI
- Charney DS, 1989, J Clin Psychiatry, 50, 418
- Charney DS, 1986, J Clin Psychiatry, 47, 580
- Chouinard G, 1990, Psychopharmacol Bull, 26, 279
- 10.3109/10401230490281609 · doi:10.3109/10401230490281609
- Davis LL, 2008, Psychopharmacol Bull, 41, 8
- DeVeaugh-Geiss J, 1989, Psychopharmacol Bull, 25, 36
- Dieleman GC, 2008, Tijdschr Psychiatr, 50, 43
- Dunner DL, 1986, J Clin Psychiatry, 47, 458
- Eriksson T, 2007, Int Clin Psychopharmacol, 22, 57
- Feighner JP, 1987, J Clin Psychiatry (Suppl), 48, 3
- Feighner JP, 1982, J Clin Psychiatry, 43, 103
- Feltner DE, 2003, J Clin Psychopharmacol, 23, 240
- Ferreri M, 1994, Encéphale, 20, 785
- 10.1037/0022-006X.65.6.1026 · doi:10.1037/0022-006x.65.6.1026
- Fesler FA, 1991, J Clin Psychiatry, 52, 361
- Foa EB, 2000, J Clin Psychiatry, 61, 43
- Frommberger U, 2004, Fortschr Neurol Psychiatr, 72, 411, 10.1055/s-2004-818455 · doi:10.1055/s-2004-818455
- Gelpin E, 1996, J Clin Psychiatry, 57, 390
- Gruber RP, 1971, Dis Nerv Syst, 32, 180
- Hamner MB, 2001, Ann Clin Psychiatry, 13, 141, 10.3109/10401230109148960 · DOI
- 10.3109/10401230009147096 · DOI · Paper page
- Hoehn-Saric R, 1988, J Clin Psychiatry, 49, 293
- Hoffart A, 1993, J Clin Psychiatry, 54, 481
- 10.1037/0022-006X.72.3.393 · DOI
- Hofmann SG, 2008, J Clin Psychiatry, e1
- Husain MM, 1993, Am J Psychiatry, 150, 1899
- Jenike MA, 1991, J Clin Psychiatry, 52, 13
- Khanna S, 1988, Convuls Ther, 4, 314
- Klerman GL, 199, Social Morbidity Health Care Utilization J, 265, 742
- Kocabasoglu N, 2004, Eur Neuropsychopharmacol, 14, S304, 10.1016/S0924-977X(04)80382-1 · doi:10.1016/s0924-977x(04)80382-1
- Koran LM, 2007, Am J Psychiatry, 164, 5
- Lee C, 2002, J Clin Psychol Psychother, 58, 1071
- Lenox-Smith AJ, 2003, Br J Gen Pract, 53, 772
- Li D, 2001, J Psychiatry Neurosci, 26, 190
- Lidren DM, 1994, J Consult Clin Psychol, 62, 865, 10.1037/0022-006X.62.4.865 · DOI · Paper page
- Liebowitz MR, 1988, J Clin Psychiatry, 49, 252
- 10.1002/(SICI)1520-6394(1999)10:3%3C89::AID-DA1%3E3.0.CO;2-5 · doi:10.1002/(sici)1520-6394(1999)10:3<89::aid-da1>3.0.co;2-5
- Livingston MG, 1994, Br J Hosp Med, 51, 281
- Lopes AC, 2008, Biol Psychiaty, 63, 131s, 10.1016/j.biopsych.2007.11.007 · doi:10.1016/j.biopsych.2007.11.007
- López-Ibor JJ, 1975, Neurological treatment in psychiatry, pain and epilepsy, 151
- Lum M, 1990, Biol Psychiatry :A, 27, 164
- Maletzky B, 1994, Convuls Ther, 10, 34
- Marazziti D, 1999, Am J Psychiatry, 156, 1834, 10.1176/ajp.156.11.1834-a · doi:10.1176/ajp.156.11.1834-a
- Marmar CR, 1996, J Clin Psychiatry, 57, 66
- Mavissakalian M, 1983, Psychopharmacol Bull, 19, 116
- Mavissakalian M, 1986, J Clin Psychol, 47, 117
- Meibach RC, 1987, J Clin Psychiatry, 48, 355
- Misri S, 2000, Can Family Phys, 46, 626
- Mohlman J, 2003, Am J Geriatr Psychiatry, 11, 24
- Montoya A, 2002, Neurosurgery, 50, 1043
- Munjack DJ, 1989, J Clin Psychopharmacol, 9, 22
- Munjack DJ, 1990, J Clin Psychiatry, 51, 35
- Nelson J, 1999, Can Soc Clin Pharmacol, 6, 69
- Neylan TC, 2006, Am J Psychiatry, 163, 2186, 10.1176/ajp.2006.163.12.2186 · doi:10.1176/ajp.2006.163.12.2186
- Nicolini H, 2008, Psychol Med, 1
- NIMH 1976. National Institute of Mental Health. 028 CGI. Clinical Global Impressions. In: Guy E, ECDEU Assessment manual for psychopharmacology. Revised edition. Rockville, MD: NIMH. p 217–222.
- Noyes R, 1996, J Clin Psychiatry, 57, 349
- Nutt DJ, 1998, J Clin Psychiatry, 59, 4
- Ontiveros A, 1992, J Psychiatry Neurosci, 17, 78
- Pastrana Jiménez JI, 2007, Actas Esp Psiquiatr, 35, 351
- Pigott TA, 1992, J Clin Psychopharmacol, 12, 11
- Pollack MH, 2003, Psychopharmacol Bull, 37, 53
- Pollack MH, 1994, J Clin Psychiatry, 55, 200
- Pollack MH, 1996, Psychopharmacol Bull, 32, 667
- Pollack MH, 1997, J Clin Psychiatry, 58, 19
- Pols H, 1993, Acta Psychiatr Belg, 93, 169
- Power KG, 1990, Br J Gen Pract, 40, 289
- Prasko J, 2006, Neuroendocrinol Lett, 27, 473
- Prasko J, 2006, Neuroendocrinol Lett, 27, 327
- 10.1034/j.1600-0447.2001.00263.x · DOI · Paper page
- Ravizza L, 1996, Psychopharmacol Bull, 32, 677
- 10.1037/0022-006X.70.4.86 · doi:10.1037/0022-006x.70.4.86
- Rickels K, 1982, J Clin Psychiatry, 43, 81
- Riddle MA, 1996, Psychopharmacol Bull, 32, 399
- Rizley R, 1986, Psychopharmacol Bull, 22, 167
- Rothbaum B, 1997, Bull Menninger Clinic, 61, 317
- Rothbaum BO, 2008, J Clin Psychiatry, e1
- Rück C, 2006, Capsulotomy in anxiety disorders [thesis]
- 10.1176/appi.ajp.164.2.290 · DOI
- 10.1002/da.20271 · DOI
- Sachdev P, 1995, J Nerv Ment Dis, 183, 408, 10.1097/00005053-199506000-00010 · doi:10.1097/00005053-199506000-00010
- 10.1345/aph.1C040 · doi:10.1345/aph.1c040 · Paper page
- Saxena S, 1996, J Clin Psychiatry, 57, 303
- Seedat S, 2004, J Clin Psychiatry, 65, 244
- Shader RI, 1993, New Engl J Med, 13, 1398
- Sharp DM, 1997, Br J Gen Pract, 47, 150
- Simon NM, 2003, Psychopharmacol Bull, 37, 66
- Simon NM, 2008, J Clin Psychiatry, e1
- Stein DJ, 1999, S Afr Med J, 89, 402
- 10.3109/10401230600948431 · doi:10.3109/10401230600948431
- Stein DJ, 2007, Eur Neuropsychophar17(Suppl, 4, S509, 10.1016/S0924-977X(07)70784-8 · doi:10.1016/s0924-977x(07)70784-8
- Strand M, 1990, J Clin Psychiatry (Suppl), 51, 40
- Telch MJ, 1995, J Consult Clin Psychol, 63, 823, 10.1037/0022-006X.63.5.823 · doi:10.1037/0022-006x.63.5.823
- Tesar GE, 1991, J Clin Psychiatry, 52, 69
- Tiffon L, 1994, J Clin Psychiatry, 55, 66
- Todorov C, 2000, Can J Psychiatry, 45, 257, 10.1177/070674370004500304 · doi:10.1177/070674370004500304
- Turner SM, 1994, J Consult Clin Psychol, 62, 350, 10.1037/0022-006X.62.2.350 · DOI · Paper page
- van Ameringen M, 1993, J Clin Psychiatry, 54, 27
- van der Kolk BA, 1994, J Clin Psychiatry, 55, 517
- Wetherell JL, 2003, J Consult Clin Psychol, 71, 31, 10.1037/0022-006X.71.1.31 · DOI · Paper page
- WHO, 1991, Clinical Descriptions and Diagnostic Guidelines
- Woodman CL, 1994, J Clin Psychiatry, 55, 134
- Worthington JJ, 1998, Psychopharmacol Bull, 34, 199
- Zitterl W, 1999, Wien Klin Wochenschr, 111, 439
- Zohar J, 2006, Obsessive-compulsive disorder and comorbidity, 79
Cited by
Epidemiology of anxiety disorders in the 21st century
Bandelow, B., & Michaelis, S. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.3/bbandelow · Cited by 2,079
Self-citationStein, D. J., Costa, D. L. C., Lochner, C., Miguel, E. C., Reddy, Y. C. J., Shavitt, R. G., van den Heuvel, O. A., & Simpson, H. B. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0102-3 · Cited by 895
Treatment of anxiety disorders
Bandelow, B., Michaelis, S., & Wedekind, D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/bbandelow · Cited by 811
Self-citationObsessive-compulsive disorder: An integrative genetic and neurobiological perspective
Pauls, D. L., Abramovitch, A., Rauch, S. L., & Geller, D. A. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3746 · Cited by 793
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Self-citation
Metadata
- Authors
- Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., & WFSBP TASK FORCE ON TREATMENT GUIDE
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2008-01
- Volume
- 9
- Issue
- 4
- Pages
- 248-312
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W1966065460
- Cited by
- 854
- References
- 826
- FWCI
- 73.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.